Clinical trials: Liver Inflammation
HBeAg(-) Chronic Hepatitis B With Compensated Liver Function
A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function
A double-blind randomized, parallel, multicenter with 48 weeks of treatment period. The purpose of this study is to compare the safety and antiviral activity of 48-week Clevudine and Adefovir dipivoxil in HBeAg(-) Chronic…
- Trial name
- NCT00641082
- Testing
- Clevudine, Adefovir dipivoxil
- Where
- 2 sites in South Korea
- Volunteers
- 43 people
- Sponsor
- Bukwang Pharmaceutical
Chronic Hepatitis C
An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)
This is a 2-part study. The purpose of Part A is to assess the efficacy and safety of grazoprevir (MK-5172) 100 mg in combination with elbasvir (MK-8742) 50 mg for 12 weeks in the treatment of chronic HCV GT1, GT4, or GT6…
- Trial name
- C-EDGE CO-STAR (NCT02105688)
- Testing
- Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)
- Volunteers
- 301 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis A Vaccine
Phase Ⅲ Clinical Trial of an Inactivated Hepatitis A Vaccine
This is a Phase Ⅲ, open-label, single arm design combined with randomized, double-blind, active-controlled design trial to assess the immunogenicity and safety of different specifications of Healive® (the 0.5 mL pediatric dosage…
- Trial name
- NCT07793227
- Testing
- Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL), Inactivated Hepatitis A Vaccine (Human Diploid Cell) (0.5 mL), Hepatitis A vaccine (inactivated, adsorbed)
- Where
- Vietnam
- Volunteers
- 680 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Hepatitis C
Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030)
The purpose of this study is to compare the plasma pharmacokinetics (PK) of single doses of MK-3682B, a fixed dose combination (FDC) tablet containing uprifosbuvir (MK-3682) + grazoprevir (MK-5172) + ruzasvir (MK-8408) in…
- Trial name
- NCT02661126
- Testing
- MK-3682B
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diphtheria, Hepatitis B
Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.
The purpose of this study is to compare the reactogenicity \& safety of Tritanrix™-HepB/Hib-MenAC vaccine to the international standard of care, Tritanrix™-HepB/Hiberix™.
- Conditions
- Diphtheria, Hepatitis B, Whole Cell Pertussis, Haemophilus Influenzae Type b
- Trial name
- NCT00317135
- Testing
- Tritanrix-HepB/Meningitec conjugate vaccine, Tritanrix/Hiberix vaccine
- Where
- Philippines
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis C
A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C
The objective of this study is to undertake an initial evaluation of the safety, tolerability, antiviral effect, and pharmacokinetics of celgosivir in combination with peginterferon alfa-2b and ribavirin in patients with chronic…
- Trial name
- NCT00332176
- Testing
- Celgosivir, Peginterferon alfa 2b + ribavirin
- Where
- 3 sites in Canada
- Volunteers
- 50 people
- Sponsor
- BioWest Therapeutics Inc
Chronic Hepatitis B
A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB
This study is divided into two parts. Part A is a multicenter, randomized, double-blind, placebo controlled phase Ill clinical trial, designed to evaluate the efficacy and safety of ZM-H1505R in combination with NAs versus NAs…
- Trial name
- NCT07095855
- Testing
- ZM-H1505R 100mg, NAs （"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"or"TMF"） treatments
- Where
- China
- Volunteers
- 1,300 people
- Sponsor
- Shanghai Zhimeng Biopharma, Inc.
Chronic Hepatitis B With Hepatic Fibrosis
A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis
This is a single-arm, multicenter, open-label Phase III clinical trial to evaluate the safety and tolerability of high-dose hydronidone capsules in patients with hepatic fibrosis and cirrhosis.
- Trial name
- NCT07343778
- Testing
- Hydronidone Capsules
- Where
- China
- Volunteers
- 337 people
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Hepatitis, Chronic
Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C
The purpose of this study is to collect information on the efficacy, safety and tolerability of telaprevir (in combination with other medications), in patients who have a history of intravenous drug use with genotype 1 chronic…
- Trial name
- INTEGRATE (NCT01980290)
- Where
- 18 sites in Belgium, France and 4 more
- Volunteers
- 50 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Hepatitis C Virus
A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1
To demonstrate the effectiveness of Daclatasvir (DCV) 3 Direct Acting Antivirals (DAA) fixed dose combination in Genotype 1 Chronic Hepatitis C subjects.
- Trial name
- UNITY 4 (NCT02170727)
- Testing
- DCV/ASV/BMS-791325
- Where
- 20 sites in Russia, South Korea and 1 more
- Volunteers
- 199 people
- Sponsor
- Bristol-Myers Squibb
HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
- Conditions
- HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C
- Trial name
- NCT07037277
- Testing
- Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir
- Where
- 107 sites in Egypt, France and 15 more
- Volunteers
- 880 people
- Sponsor
- Atea Pharmaceuticals, Inc.
Chronic Hepatitis C
Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed
SCV-07 (γ-D-glutamyl-L-tryptophan) is a new immunomodulatory compound that has been developed and patented both for composition and immunomodulatory use and is a synthetic dipeptide.
- Trial name
- NCT00968357
- Testing
- SCV-07
- Where
- 16 sites in United States
- Volunteers
- 40 people
- Sponsor
- SciClone Pharmaceuticals
Exposure to Hepatitis B Virus
Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine
There is a need for more effective and better-tolerated hepatitis B vaccines for low responder high-risk populations including patients with renal impairment and/or diabetes mellitus and those aged over 40 years.
- Trial name
- NCT01951677
- Testing
- HBsAg, PreS HBsAg, Advax-1(TM)
- Where
- Australia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
Hepatitis C, Chronic, Substance Abuse, Intravenous
Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261)
Previous intravenous drug abusers with chronic hepatitis C who are under substitution therapy (buprenorphine, methadone) will be treated with PegIntron and Rebetol according to the approved European labeling.
- Trial name
- SUPPORT (NCT00726557)
- Testing
- PegIntron (pegylated interferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 246 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)
This is a 2 part study of the safety, pharmacokinetics and pharmacodynamics of MK-6325 in HCV-infected participants. Part I of the study will be for Genotype (GT) 1 HCV-infected participants who will be randomized to receive…
- Trial name
- NCT01329913
- Testing
- MK-6325
- Volunteers
- 36 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Participants
A Study to Investigate the Potential Pharmacokinetic Interactions Between Phenytoin or Carbamazepine and Telaprevir
The purpose of this study is to investigate the potential pharmacokinetic (what the body does to the drug) interactions between multiple doses of phenytoin 200 mg every 12 hours or carbamazepine 200 mg every 12 hours and…
- Trial name
- NCT01635829
- Testing
- Telaprevir, Phenytoin, Carbamazepine
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Infectious Diseases BVBA
Chronic Hepatitis B
Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B
The primary objectives of this study are to evaluate the safety, tolerability and antiviral activity of selgantolimod (formerly GS-9688) in virally suppressed chronic hepatitis B (CHB) adults on oral antiviral (OAV) agents.
- Trial name
- NCT03491553
- Testing
- Selgantolimod, Hepatitis B virus (HBV) OAV Therapy
- Where
- 2 sites in United States, New Zealand
- Volunteers
- 48 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks in participants with chronic hepatitis C virus…
- Trial name
- NCT02722837
- Testing
- SOF/VEL
- Where
- 15 sites in Russia, Sweden
- Volunteers
- 119 people
- Sponsor
- Gilead Sciences
Hepatitis B
Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age
Primary Objective: To describe the persistence of Hep B antibodies (Ab) at 12 to 18 months of age following a three-dose infant primary series vaccination of either Hexaxim®/Hexyon®/Hexacima® or Infanrix® hexa at 2, 4 and 6…
- Trial name
- NCT02610348
- Testing
- DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines, DTaP-HB-IPV and Pneumococcal polysaccharide vaccines
- Where
- 2 sites in Thailand
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hepatitis B
Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B as Control
The purpose of the present study is to evaluate the immunogenicity and safety of three consecutive production lots of the novel adjuvanted HBV vaccine.
- Trial name
- NCT00697866
- Testing
- HBV-MPL vaccine 208129, Engerix™-B
- Volunteers
- 951 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.